Annexon Inc (ANNX) Stock Price, Quote & News

Company Profile

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also devel...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 822 5500

Fax: 650 636 9773

Website: www.annexonbio.com

Address:

1400 Sierra Point Parkway, Building C Suite 200, Brisbane, United States

macd87 Oct. 4 at 12:12 AM

$ANNX Qwen3-Max Possible Analyses or Actions: Identify key support/resistance levels based on highs/lows. Calculate price trends (e.g., moving averages, % change over time). Spot unusual volume spikes (e.g., July 10 or March 17) and correlate with price action. Find the lowest/highest prices in the period. Detect potential breakouts or breakdowns. Plot the data (if you’re using Python/Pandas, I can provide code). Calculate volatility (e.g., average true range or daily range = High – Low). Summarize performance (e.g., total return from start to end). Biggest single-day volume: 7,998,400 on 2025-07-10, which also saw a massive intraday drop (High: 2.96 → Low: 1.85). This suggests a potential panic sell-off or news event. Highest price: 3.51 on 2025-03-17 (also high volume: 4.26M). Lowest price: 1.28 on 2025-04-10. Recent strength: Price has climbed from ~1.28 (April) to 3.38 (Oct 3), more than 2.6x in 6 months.

0 · Reply

Thomas105 Oct. 3 at 2:28 PM

$ANNX The stock is rising despite the lack of news. I'm in favor of the theory that it will continue like this. I'm just curious to see if the 7.85 mark will be broken when we get to that point.

0 · Reply

Acan1219 Oct. 3 at 1:46 PM

$ANNX I’ve been saying this is a double digit stock! It’s coming my Bull’s!!💰💰

0 · Reply

Abundance11 Oct. 3 at 1:43 PM

$ANNX bearish sentiment? Lol..how, its been up for a month.

0 · Reply

Consti22 Oct. 3 at 1:40 PM

$ANNX Did we miss something? 😏🤩💪

0 · Reply

Consti22 Oct. 2 at 8:37 PM

$ANNX

0 · Reply

jjrrjjrr Oct. 2 at 6:14 PM

$BLNE $ANNX NFA $BTC.X

0 · Reply

raj3406 Oct. 2 at 12:29 AM

$ANNX Tomorrow we going back to 3.30?

2 · Reply

BillionerOfKing Oct. 1 at 3:24 PM

$ANNX Current Stock Price: $3.10 Contracts to trade: $5 ANNX Oct 17 2025 Call Entry: $0.01 Exit: $0.01 ROI: 61% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

LiquidThetaLEAPS Sep. 30 at 10:45 PM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ANNX Current Share Price: $3.06 Contracts: $ANNX December 18, 2026 $4 Calls Scale in: $0.97- $1.18 Scale out: $1.50-$1.94 Can Easily Capture: 60% ROI Blended DTE: 445 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

Annexon, Inc. (ANNX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 5, 2025, 1:38 AM EDT - 4 weeks ago

Annexon, Inc. (ANNX) Presents at Cantor Global Healthcare Conference 2025 Transcript

Aug 27, 2025, 8:00 AM EDT - 5 weeks ago

Annexon Biosciences to Participate in Upcoming September Investor Conferences

Aug 18, 2025, 4:05 PM EDT - 6 weeks ago

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Aug 14, 2025, 4:05 PM EDT - 7 weeks ago

Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Aug 7, 2025, 4:30 PM EDT - 2 months ago

Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy

Jul 24, 2025, 7:00 AM EDT - 2 months ago

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy

Jul 14, 2025, 12:47 PM EDT - 2 months ago

Annexon: Lead GBS Therapy Stokes Near-Term Potential

Jun 18, 2025, 4:05 PM EDT - 3 months ago

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)

May 29, 2025, 4:05 PM EDT - 4 months ago

Annexon Biosciences to Present at the Jefferies Global Healthcare Conference

May 19, 2025, 4:05 PM EDT - 4 months ago

Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting

May 16, 2025, 4:05 PM EDT - 5 months ago

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

May 12, 2025, 8:00 AM EDT - 5 months ago

Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

May 9, 2025, 5:00 PM EDT - 5 months ago

Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting

May 7, 2025, 8:00 AM EDT - 5 months ago

Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress

Apr 15, 2025, 7:12 AM EDT - 6 months ago

Annexon: With IGOS Study Completion, Pre-BLA Meeting In 1st Half 2025 On Deck

Apr 8, 2025, 4:05 PM EDT - 6 months ago

Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting

Apr 3, 2025, 6:18 PM EDT - 6 months ago

Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting

Mar 3, 2025, 8:00 AM EST - 7 months ago

Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones

Feb 26, 2025, 4:05 PM EST - 7 months ago

Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference

Feb 13, 2025, 8:30 AM EST - 8 months ago

Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting

Jan 7, 2025, 8:00 AM EST - 9 months ago

Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 16, 2024, 7:30 AM EST - 10 months ago

Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)

Nov 14, 2024, 8:00 AM EST - 11 months ago

Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones

Nov 13, 2024, 4:05 PM EST - 11 months ago

Annexon Biosciences to Present at the Jefferies London Healthcare Conference

Oct 21, 2024, 8:00 PM EDT - 1 year ago

Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

Oct 3, 2024, 1:20 AM EDT - 1 year ago

Director William Carson Acquires 3,200 Shares of Annexon Inc (ANNX)

Aug 17, 2024, 9:28 AM EDT - 1 year ago

Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS

Jul 11, 2024, 6:09 PM EDT - 1 year ago

Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting

Jun 25, 2024, 5:00 PM EDT - 1 year ago

Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting

Jun 5, 2024, 11:04 PM EDT - 1 year ago

Annexon Announces Pricing of $125 Million Underwritten Public Offering

Jun 4, 2024, 5:06 PM EDT - 1 year ago

Annexon Announces Proposed Public Offering of Common Stock

Jun 4, 2024, 2:07 PM EDT - 1 year ago

Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

Jun 4, 2024, 7:11 AM EDT - 1 year ago

Annexon's neurological disorder drug meets main goal of late-stage study

Jun 3, 2024, 4:30 PM EDT - 1 year ago

Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data

May 13, 2024, 8:00 AM EDT - 1 year ago

Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones

May 9, 2024, 8:00 AM EDT - 1 year ago

Annexon Biosciences to Present at the Bank of America Health Care Conference

May 7, 2024, 12:30 PM EDT - 1 year ago

Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting

May 1, 2024, 8:00 AM EDT - 1 year ago

Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting

Apr 3, 2024, 8:00 AM EDT - 1 year ago

Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 26, 2024, 4:05 PM EDT - 1 year ago

Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones

Feb 27, 2024, 8:00 AM EST - 1 year ago

Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference

Feb 21, 2024, 8:00 AM EST - 1 year ago

Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon's Novel Therapeutic Approach

Jan 7, 2024, 8:00 PM EST - 1 year ago

Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases

Dec 27, 2023, 6:30 AM EST - 1 year ago

Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 23, 2023, 12:00 PM EST - 1 year ago

Annexon: ANX007 Advances Forward With Stellar Endpoint

Dec 20, 2023, 5:27 PM EST - 1 year ago

Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock

Dec 20, 2023, 5:10 PM EST - 1 year ago

Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint

Dec 20, 2023, 5:08 PM EST - 1 year ago

Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway

Nov 22, 2023, 4:01 PM EST - 2 years ago

Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference

macd87 Oct. 4 at 12:12 AM

0 · Reply

Thomas105 Oct. 3 at 2:28 PM

$ANNX The stock is rising despite the lack of news. I'm in favor of the theory that it will continue like this. I'm just curious to see if the 7.85 mark will be broken when we get to that point.

0 · Reply

Acan1219 Oct. 3 at 1:46 PM

$ANNX I’ve been saying this is a double digit stock! It’s coming my Bull’s!!💰💰

0 · Reply

Abundance11 Oct. 3 at 1:43 PM

$ANNX bearish sentiment? Lol..how, its been up for a month.

0 · Reply

Consti22 Oct. 3 at 1:40 PM

$ANNX Did we miss something? 😏🤩💪

0 · Reply

Consti22 Oct. 2 at 8:37 PM

$ANNX

0 · Reply

jjrrjjrr Oct. 2 at 6:14 PM

$BLNE $ANNX NFA $BTC.X

0 · Reply

raj3406 Oct. 2 at 12:29 AM

$ANNX Tomorrow we going back to 3.30?

2 · Reply

BillionerOfKing Oct. 1 at 3:24 PM

0 · Reply

LiquidThetaLEAPS Sep. 30 at 10:45 PM

0 · Reply

Thomas105 Sep. 30 at 6:30 PM

$ANNX

0 · Reply

highnihilism Sep. 30 at 10:22 AM

$PESI Perma-Fix: 19 trades, $34K vs $24K avg (1.44x). $33K calls / $1K puts. $ANNX Annexon: 56 trades, $34K vs $20K avg (1.70x). $33K calls / $1K puts. $OMI Owens & Minor: 38 trades, $37K vs $86K avg (0.43x !!). $33K calls / $4K puts. $EVR Evercore: 18 trades, $38K vs $899K avg (0.04x !!!!). $33K calls / $5K puts.

0 · Reply

Gurujoe Sep. 29 at 6:35 PM

$ANNX Attached is the link (US trials) to the open label, 30 patients in US & Europe which was registered June 30th. Also attached is the Poster presentation at major medical conference about the open label study in September. https://clinicaltrials.gov/study/NCT07020819?intr=Tanruprubart&rank=1 https://annexonbio.com/wp-content/uploads/2025/09/GBS-FORWARD-Study-Design-Poster-for-NCS_Final.pdf

1 · Reply

makingdoughfromoptions Sep. 29 at 5:57 PM

$ANNX Friday: Announced a US trial from GBS. Small, 30 patients....obviously requested by FDA. That is good as it shows a possible path to approval. Today, profit taking.

1 · Reply

prismmarketview Sep. 29 at 4:40 PM

PRISM Miday Market Update: Pharmaceuticals & biotech names are powering today’s breakouts — high momentum across drug developers is driving sharp gains in the small/mid-caps. Applied Therapeutics ( $APLT), which has surged over 121% Annexon ( $ANNX), which is leading sector gains with a sharp rise of nearly 21%. Fractyl Health ( $GUTS) Up 32.67% eShape Lifesciences Inc. ( $RSLS) Up 22.5% https://prismmarketview.com/prism-mid-day-market-update-pharmaceuticals-biotech-lead-with-big-breakouts/

0 · Reply

Rickylinderman Sep. 29 at 4:23 PM

$ANNX schlonged. Whew

0 · Reply

BooEmmy Sep. 29 at 4:01 PM

$ANNX I'm a little confused with this stock. It rallies 20% Friday with 5m in volume and no news and then drifts off today on small volume and no news. Are we waiting for news? Oh and nobody makes any comments on this board at all.

3 · Reply

LiquidThetaLEAPS Sep. 29 at 8:00 AM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ANNX Current Share Price: $3.37 Contracts: $ANNX December 18, 2026 $4 Calls Scale in: $0.97- $1.18 Scale out: $1.50-$1.94 Can Easily Capture: 60% ROI Blended DTE: 446 Days | Join Elites here: https://liquidtheta.com

0 · Reply

LiquidThetaLEAPS Sep. 27 at 5:13 PM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ANNX Current Share Price: $2.81 Contracts: $ANNX December 18, 2026 $3 Calls Scale in: $0.90- $1.10 Scale out: $1.40-$1.80 Can Easily Capture: 60% ROI Blended DTE: 448 Days | Join Elites here: https://liquidtheta.com

0 · Reply

josegodoy Sep. 27 at 11:18 AM

$ANNX PT range $3.60 >>>> $4.00 (looks pretty good (so $3.60 is 💰pretty much)) - simple line (daily) An opinion

0 · Reply

Consti22 Sep. 27 at 5:34 AM

$ANNX A huge climb. I wouldn't have expected it on a Friday. 🤩💪

1 · Reply

Acan1219 Sep. 26 at 10:28 PM

$ANNX 🚀🚀🚀

0 · Reply

Market Cap	341.75M
Revenue (ttm)	0.00
Net Income (ttm)	-138.20M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,518,100
Avg Vol	1,701,320
Day's Range	N/A - N/A
Shares Out	109.89M
Stochastic %K	65%
Beta	1.36
Analysts	Strong Sell
Price Target	$11.60